Icahn School of Medicine at Mount Sinai, New York City, New York.
Icahn School of Medicine at Mount Sinai, New York City, New York.
Semin Oncol. 2020 Apr-Jun;47(2-3):155-164. doi: 10.1053/j.seminoncol.2020.04.004. Epub 2020 May 8.
Management of multiple myeloma represents an ever changing paradigm with monoclonal antibodies adding the ability to treat patients with 3 and 4 drug regimens with acceptable toxicity profiles. In recent years, we have seen the FDA approve a number of regimens with both elotuzumab and daratumumab in combination with the standard approaches of immunomodulatory drugs, proteasome inhibitors, and steroids. Isatuximab is a naked, humanized IgG1 monoclonal antibody directed against CD38. With the recent FDA approval in March 2020, we seek to summarize the presented data to date and where this drug will fit into the future gestalt of myeloma therapy.
多发性骨髓瘤的治疗模式在不断变化，单克隆抗体的出现使我们能够用 3 种和 4 种药物方案来治疗患者，且毒性可接受。近年来，我们看到 FDA 批准了许多方案，将埃罗妥珠单抗和达妥昔单抗与免疫调节剂、蛋白酶体抑制剂和类固醇联合使用。依沙妥昔单抗是一种针对 CD38 的天然、人源化 IgG1 单克隆抗体。随着 2020 年 3 月 FDA 的批准，我们试图总结迄今为止的研究数据，并探讨该药在多发性骨髓瘤治疗中的未来定位。
